Vertex casually drops Orkambi revenue slowdown, creating
Por um escritor misterioso
Descrição
Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.
S-1
October, 2015
424B4
Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors
S-1
Vertex Pharmaceuticals' Revenue by Product (2016-2023)
Vertex Reports First Quarter 2023 Financial Results
Vertex to shutter Canada site, focus in on 3 hubs in R&D shuffle
SEC Filing – Royalty Pharma
Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors
SEC Filing – Royalty Pharma
de
por adulto (o preço varia de acordo com o tamanho do grupo)